Longevity Medicine
What Is Genetic Cancer Risk Testing?
Last reviewed: May 2026 · Haute MD Editorial Team
Genetic cancer risk testing — also called germline or hereditary cancer testing — uses a blood or saliva sample to identify inherited DNA mutations that significantly increase lifetime risk of certain cancers. Identifying these mutations enables tailored, more intensive screening; risk-reducing surgery; targeted therapies; and informed family member testing.
What genes are tested and why
Modern multi-gene panels test 30-90+ cancer predisposition genes simultaneously. Highest-impact genes include: BRCA1/BRCA2 (breast, ovarian, prostate, pancreatic), Lynch syndrome genes — MLH1, MSH2, MSH6, PMS2, EPCAM (colorectal, endometrial, gastric, ovarian, urothelial), TP53 (Li-Fraumeni — multiple early-onset cancers), PALB2 (breast, pancreatic), ATM and CHEK2 (breast, others), CDH1 (gastric, lobular breast), APC (familial adenomatous polyposis — colorectal), MUTYH (colorectal), PTEN (Cowden syndrome), STK11 (Peutz-Jeghers), CDKN2A (melanoma, pancreatic), and BAP1 (melanoma, mesothelioma, kidney). A pathogenic variant carrier may have 5-90% lifetime risk of certain cancers depending on the gene.
Who should be tested
Historically testing was reserved for those meeting strict family history criteria, but expanded testing is increasingly common. Strong indications include: personal cancer history (especially early-onset, bilateral, or multiple primary cancers), Ashkenazi Jewish ancestry (~1 in 40 carry a BRCA founder mutation), multiple first/second-degree relatives with the same or related cancers, a known mutation in the family, certain cancer types regardless of family history (ovarian, pancreatic, male breast, metastatic prostate, triple-negative breast under 60, colorectal under 50). Some longevity practices offer broader testing to all interested adults given that ~3-5% of unselected adults carry an actionable pathogenic variant — many without family history that would have triggered testing. Pre-test genetic counseling clarifies implications and informed consent.
What changes if a mutation is identified
(1) Enhanced screening — BRCA carriers begin breast MRI annually starting at 25-30, alternating with mammography; Lynch carriers begin colonoscopy at 20-25 with 1-2 year intervals; (2) Risk-reducing surgery — BRCA1 carriers often consider bilateral salpingo-oophorectomy by age 35-40 (reduces ovarian cancer ~80% and breast cancer ~50%); some elect prophylactic mastectomy; (3) Targeted therapy — PARP inhibitors are effective in BRCA-mutated and HRR-deficient cancers; immunotherapy responsiveness differs in Lynch syndrome; (4) Cascade testing — first-degree relatives are tested for the family mutation, identifying high-risk individuals before any cancer develops; (5) Reproductive planning — preimplantation genetic testing can avoid passing the mutation to children. A pathogenic variant is not destiny — many carriers never develop cancer — but knowledge enables substantial risk reduction. Conversely, a negative test in a family with known mutation reliably reduces risk to population baseline.
Frequently Asked Questions
Is genetic cancer testing covered by insurance?
Generally yes when meeting NCCN testing criteria (family or personal history). Out-of-pocket cost has fallen substantially — multi-gene panels are often $250-$500 without insurance. Several companies offer no-cost testing for eligible patients.
Does a positive result raise insurance premiums?
The Genetic Information Nondiscrimination Act (GINA, 2008) protects against health insurance and employment discrimination based on genetic results. GINA does not cover life, long-term care, or disability insurance — a consideration for some patients.
What if I'm BRCA-positive — must I have surgery?
No. Many BRCA carriers manage risk with enhanced screening alone. Risk-reducing surgery is discussed and individualized — bilateral salpingo-oophorectomy is more commonly recommended by 35-40 in BRCA1 and slightly later in BRCA2 because there is no effective ovarian cancer screening; mastectomy is more clearly elective.
Should my family members be tested?
Yes — first-degree relatives have a 50% chance of inheriting the same mutation. Cascade testing is one of the highest-yield interventions in genetic medicine. Most laboratories offer reduced-cost or free testing for relatives of identified carriers.
Get Help Now
Speak with a Haute MD Longevity Medicine physician
Dr. George Kaltner
CEO
Longevity Medicine · Miami Beach, FL
View Profile
Dr. Alexander Golberg
Longevity Medicine · New York, NY
View Profile
Dr. Steven Victor
Regenerative Medicine Specialist
Longevity Medicine · New York, NY
View ProfileAre you a Longevity Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · LONGEVITY MEDICINE
What Is Preventive Oncology?
Preventive oncology applies risk stratification, advanced screening, and lifestyle interventions to detect cancer earlier and reduce lifetime cancer risk.
Read GuideGuide · LONGEVITY MEDICINE
What Is Multi-Cancer Early Detection?
Multi-cancer early detection (MCED) tests screen for dozens of cancers from a single blood sample using DNA methylation signatures.
Read GuideGuide · LONGEVITY MEDICINE
What Is Liquid Biopsy?
Liquid biopsy is a blood test that detects circulating tumor DNA and other cancer-derived material to enable earlier detection and monitoring.
Read Guide